Home » Stocks » REGN

Regeneron Pharmaceuticals, Inc. (REGN)

Stock Price: $586.35 USD -0.53 (-0.09%)
Updated Jul 23, 2021 4:00 PM EDT - Market closed
Market Cap 62.41B
Revenue (ttm) 9.20B
Net Income (ttm) 4.00B
Shares Out 105.40M
EPS (ttm) 35.13
PE Ratio 16.69
Forward PE 12.50
Dividend n/a
Dividend Yield n/a
Trading Day July 23
Last Price $586.35
Previous Close $586.88
Change ($) -0.53
Change (%) -0.09%
Day's Open 588.83
Day's Range 583.74 - 595.48
Day's Volume 628,252
52-Week Range 441.00 - 660.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) started their collaboration in chronic obstructive pulmonary disorder (COPD) to target all patients, and the data is pointing the...

Other stocks mentioned: SNY
1 day ago - Benzinga

REGN vs. INCY: Which Stock Is the Better Value Option?

Other stocks mentioned: INCY
1 day ago - Zacks Investment Research

The stock price of Regeneron has seen a 9% rise over the last twenty-one trading days, while it is down 8% over the last year. The volatility in REGN stock is being driven by the developments for REGEN-...

2 days ago - Forbes

In the latest trading session, Regeneron (REGN) closed at $583.72, marking a -0.6% move from the previous day.

2 days ago - Zacks Investment Research

Is (REGN) Outperforming Other Medical Stocks This Year?

2 days ago - Zacks Investment Research

It is imperative to build a portfolio of low-beta stocks to sail through choppy market conditions. DG, CAJ, TYL, REGN & FANH are the frontrunners.

Other stocks mentioned: CAJ, DG, FANH, TYL
3 days ago - Zacks Investment Research

Regeneron's(REGN) cocktail for the treatment of COVID-19 gets approval in Japan as Ronapreve.

3 days ago - Zacks Investment Research

TARRYTOWN, N.Y., July 20, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Regeneron's casirivi...

4 days ago - PRNewsWire

Regeneron (REGN) closed at $589.32 in the latest trading session, marking a +1.42% move from the prior day.

1 week ago - Zacks Investment Research

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

1 week ago - Zacks Investment Research

This biotech giant might be down, but it isn't out just yet.

1 week ago - The Motley Fool

Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

1 week ago - Zacks Investment Research

Now's the time to get into these companies while their valuation is still favorable.

Other stocks mentioned: BAYRY, PFE
1 week ago - The Motley Fool

The latest guideline update by the WHO includes the use of arthritis drugs like Roche's (RHHBY) Actemra and Sanofi's (SNY) Kevzara for the treatment of severe COVID-19.

Other stocks mentioned: LLY, RHHBY, SNY
2 weeks ago - Zacks Investment Research

The biopharma outfit dropped news that may mean more for the medicine industry than anybody fully understands.

2 weeks ago - The Motley Fool

TARRYTOWN, N.Y., July 7, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2021 financial and operating results on Thursday, Augu...

2 weeks ago - PRNewsWire

Here we present three biotech companies, which outperformed the sector in the year so far and are likely to witness a winning run in the near term.

Other stocks mentioned: AMGN, BIIB, BNTX, MRNA, NTLA, RGEN
2 weeks ago - Zacks Investment Research

Regeneron's COVID-19 treatment is getting easier to administer -- and produce.

2 weeks ago - The Motley Fool

Here's how several leading COVID-19 antibody therapies compare based on pre-clinical testing.

Other stocks mentioned: ABBV, AZN, LLY, VIR
3 weeks ago - The Motley Fool

Regeneron's (REGN) efforts to expand the label of its approved drugs and concurrently develop the pipeline are impressive and makes it a good bet for investors, for now.

3 weeks ago - Zacks Investment Research

Regeneron (REGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

3 weeks ago - Zacks Investment Research

A team at Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) Genetics Center has discovered mutations in the gene GPR75 that protect against obesity. Now, drug developers at Regeneron will use its VelocImmu...

3 weeks ago - Benzinga

Square, Regeneron, Walgreen and CrowdStrike were our top stock trades for Friday. Let's get a look at how the charts are setting up now.

Other stocks mentioned: SQ, CRWD, WBA
3 weeks ago - InvestorPlace

TARRYTOWN, N.Y., July 1, 2021 /PRNewswire/ -- Publication in Science reports that people with these protective mutations have 54% reduced risk of obesity Regeneron used its VelociGene® technology to cre...

3 weeks ago - PRNewsWire

The genomic-editing space has come under the spotlight with the release of encouraging data from a study assessing an in vivo CRISPR-based gene editing therapy candidate, NTLA-2001.

Other stocks mentioned: ARKG, BEAM, CRSP, EDIT, GNOM, IDNA, NTLA
3 weeks ago - Zacks Investment Research

Regeneron Pharmaceuticals Inc.'s (NASDAQ:REGN) robust pipeline and attractive valuation has prompted an analyst at HC Wainwright to join the bullish camp. The Regeneron Analyst: Analyst Michael King ini...

3 weeks ago - Benzinga

Early data is very promising: Biotech analyst on CRISPR technology

YouTube video

Intellia is soaring after promising trial results using CRISPR technology. Alethia Young, Cantor Fitzgerald senior biotech analyst, joins 'Closing Bell' to discuss the significance of the trial and what...

Other stocks mentioned: NTLA
3 weeks ago - CNBC Television

Find out why these stocks are climbing higher.

Other stocks mentioned: NTLA, VERV
3 weeks ago - The Motley Fool

REGN vs. INCY: Which Stock Is the Better Value Option?

Other stocks mentioned: INCY
3 weeks ago - Zacks Investment Research

Is (REGN) Outperforming Other Medical Stocks This Year?

3 weeks ago - Zacks Investment Research

Intellia, Regeneron complete first systemic delivery of CRISPR in body

YouTube video

CNBC's Meg Tirrell reports on Regeneron and Intellia's CRISPR gene-editing first.

Other stocks mentioned: NTLA
3 weeks ago - CNBC Television

Dupixent ® (dupilumab) SmPC update d with long-term data reinforc ing well -established safety profile in adults with moderate-to-severe atopic dermatitis

3 weeks ago - GlobeNewsWire

TARRYTOWN, N.Y. and PARIS, June 28, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Medicines Agency will update the Dupixent® (dupilumab...

3 weeks ago - PRNewsWire

Regeneron (REGN) and partner Sanofi win EC approval for Libtayo for skin cancer and lung cancer.

Other stocks mentioned: SNY
4 weeks ago - Zacks Investment Research

The European Commission (EC) has approved Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) Libtayo (cemiplimab) for two additional indications - basal cell carcinoma (BCC) and ...

Other stocks mentioned: SNY
4 weeks ago - Benzinga

TARRYTOWN, N.Y. and PARIS, June 25, 2021 /PRNewswire/ --  Approval based on data from the largest trial to date in patients with advanced basal cell carcinoma previously treated with a hedgehog pathway ...

4 weeks ago - PRNewsWire

Libtayo ® ( cemiplimab ) approve d by the European Commission for first-line treatment of patients with advanced non-small cell lung cancer with ≥50% PD - L 1 expressio n

4 weeks ago - GlobeNewsWire

TARRYTOWN, N.Y. and PARIS, June 25, 2021 /PRNewswire/ --  Approval based on a Phase 3 trial demonstrating Libtayo significantly improved overall survival compared to chemotherapy in advanced NSCLC that ...

4 weeks ago - PRNewsWire

These companies are generating tons of free cash and don't need to rely on debt to grow.

Other stocks mentioned: COST, FB
1 month ago - The Motley Fool

TARRYTOWN, N.Y., June 22, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is scheduled to participate in a virtual fireside chat at the Guggenheim Biopharma Strategy Series – Biophar...

1 month ago - PRNewsWire

The market is mispricing these names, ignoring the long-term growth prospects ahead for each of them.

Other stocks mentioned: EBAY, VIAC
1 month ago - The Motley Fool

Delays in FDA approval for Incyte could spell good news for Sanofi.

Other stocks mentioned: ABBV, INCY, LLY, PFE, SNY
1 month ago - The Motley Fool

All the major indexes pulled back on again Wednesday, and again the Nasdaq led the charge lower.

Other stocks mentioned: AMD, BAC, VRTX
1 month ago - 24/7 Wall Street

Regeneron's antibody drug reduces risk of death in some Covid patients

YouTube video

CNBC's Meg Tirrell joins ‘The News with Shepard Smith' to discuss the Regeneron antibody drug, which reduces the risk of death by 20% in some Covid patients. The drug is a combination of two antibodies ...

1 month ago - CNBC Television

Regeneron's life-saving antibody drug , FTC chair's serious antitrust tone

YouTube video

Yahoo Finance's Julie Hyman breaks down today's business headlines, including: An antibody treatment created by Regeneron being able to cut the risk of death from COVID-19, rent for single-families goin...

1 month ago - Yahoo Finance

RAPT up on positive data from an early-stage study in patients with moderate-to-severe atopic dermatitis.

Other stocks mentioned: RAPT, RGEN, SNY
1 month ago - Zacks Investment Research

Regeneron (REGN) announces positive results from a phase III study on antibody cocktail, REGEN-COV.

1 month ago - Zacks Investment Research

Regeneron to ask FDA to expand EUA for antibody treatment after positive study results

YouTube video

A study found that an antibody combination made by Regeneron reduces the risk of death when given to patients with severe Covid who have not mounted a natural antibody response of their own. CNBC's Meg ...

1 month ago - CNBC Television

Regeneron antibody treatment reduces risk of death in hospitalized Covid patients, study finds

YouTube video

An antibody combination made by Regeneron reduces the risk of death when given to patients with severe Covid-19 who have not mounted a natural antibody response of their own. Dr. Scott Gottlieb, member ...

1 month ago - CNBC Television

The company, whose treatment was used on former President Trump after he was diagnosed with the virus, said it will ask the FDA to expand its emergency use authorization in the U.S. to reach more patients.

1 month ago - Forbes

About REGN

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent i... [Read more...]

Industry
Biotechnology
IPO Date
Apr 2, 1991
CEO
Leonard Schleifer
Employees
9,447
Stock Exchange
NASDAQ
Ticker Symbol
REGN
Full Company Profile

Financial Performance

In 2020, REGN's revenue was $8.50 billion, an increase of 29.58% compared to the previous year's $6.56 billion. Earnings were $3.51 billion, an increase of 66.05%.

Financial Statements

Analyst Forecasts

According to 27 analysts, the average rating for REGN stock is "Buy." The 12-month stock price forecast is 638.39, which is an increase of 8.88% from the latest price.

Price Target
$638.39
(8.88% upside)
Analyst Consensus: Buy